Multicentre Clinical Trial to Assess the Performance of Centralized Assays for Hepatitis C Virus RNA Detection From Dried Blood Spot (DBS) Samples
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 942
- 试验地点
- 8
- 主要终点
- Evaluation of the correlation of HCV viral load level determined by each assay performed from DBS and/or PSC specimens with the HCV viral load level in plasma determined by Abbott RealTime HCV VL assay performed at the clinical site
研究概览
简要总结
FIND is preparing a study to evaluate the performance, as measured by sensitivity and specificity, of four centralized assays for the detection of HCV RNA using capillary blood collected on dried blood spots (DBS) and plasma separation card (PSC).
详细描述
Available data on the performance of HCV RNA assays from DBS samples are insufficient to introduce their use in clinical practice. Only a few studies have been performed on DBS stored at ambient temperature, while the majority had DBS samples refrigerated or frozen right after collection, which does not mimic real-life settings. Additionally, due to the lack of standardized procedures, DBS collection and elution protocols varied across different studies. A large multicentre diagnostic accuracy study using standardized DBS collection and elution protocols validated by test manufacturers is needed to inform national hepatitis programmes and international guideline development groups. Test manufacturers need clinical evaluation data to update their regulatory claims and include DBS as an alternative sample type.
FIND is preparing a trial to evaluate the performance, as measured by sensitivity and specificity, of four laboratory-based assays for detection of HCV RNA assays using capillary blood collected on DBS/PSC. This will be provisional on the manufacturers agreeing to participate, as well as committing to applying to stringent regulatory approval for DBS/PSC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Three different population groups will be considered:
- •Individuals at risk of having HCV infection based on positive HCV serology test results
- •Inclusion criteria:
- •Aged 18 years or older
- •Able to understand the scope of the trial
- •Provided written informed consent
- •Documented positive result of HCV serology test
- •Individuals at risk of having HCV infection based on past and/or current exposure to risk factors
- •Inclusion criteria:
- •Aged 18 years or older
- •Able to understand the scope of the trial
- •Provided written informed consent
- •Past and/or current exposure to one of the high risk factors as defined by WHO and CDC guidelines (Appendix I)
- •Individuals diagnosed with chronic HCV infection who initiated or completed the anti-HCV treatment with direct acting antivirals (DAA) presenting at the clinical site for treatment monitoring or test of cure (i.e. sustained virological response)
- •Inclusion criteria:
- •Aged 18 years or older
- •Able to understand the scope of the trial
- •Provided written informed consent
- •Initiated on DAA treatment (regardless of type of DAA regimen) within 12 months prior to the enrolment to the trial
排除标准
- •(for all trial populations):
- •Previously enrolled in the trial
- •Unwilling to provide required volume of fingerstick blood
- •Unwilling to provide required volume of venous whole blood
结局指标
主要结局
Evaluation of the correlation of HCV viral load level determined by each assay performed from DBS and/or PSC specimens with the HCV viral load level in plasma determined by Abbott RealTime HCV VL assay performed at the clinical site
时间窗: day 1 - day 30
Evaluation of the correlation of HCV viral load level determined by each assay performed
Point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection from DBS and/or PSC specimens measured against Abbott RealTime HCV VL assay performed at the clinical site
时间窗: day 1 - day 30
Point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection from DBS and/or PSC specimens measured against Abbott RealTime HCV VL assay performed at the clinical site
次要结局
- WHO technician's appraisal sheet completed by all operators performing investigational test(through study completion, an average of 1 year)
- evaluation of the correlation of HCV RNA levels in plasma determined by each assay with HCV RNA levels in plasma determined by Roche cobas® 6800 HCV VL assay(day 7 - day 30)
- Point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection from DBS and/or PSC specimens measured against the performance of the same assay in plasma(day 1 - day 30)
- Evaluation of the correlation of HCV viral load level determined by each assay performed from DBS and/or PSC specimens with the HCV RNA level in plasma determined by the same assay(day 1 - day 30)
- point estimates (with 95% confidence intervals) of sensitivity and specificity for each assay for HCV RNA detection in plasma measured against the performance of Roche cobas® 6800 HCV VL assay(day 7 - day 30)